# Step 8: Evidence Reliability and Dissemination Recommendation

Date completed: 2026-09-22

## Bottom Line

The generated evidence is reliable for documenting a transparent, reproducible, internally consistent adjusted observational association in this analytic dataset. It is not reliable enough, on its own, to support a definitive causal claim, regulatory-grade conclusion, clinical practice change, or broad public dissemination as established evidence.

The most appropriate dissemination is internal scientific communication, methods demonstration, hypothesis generation, and planning for a more complete OHDSI-style study with richer source data and external validation.

## Evidence Claim Supported

The evidence supports the following cautious claim:

> In this de-identified analytic dataset, patients in `COHORT_ID = 1` had higher observed adverse event risk than patients in `COHORT_ID = 0`; this association persisted after adjustment for age, race, pain level, and LDL using outcome regression and propensity-score weighting.

The evidence does not support the stronger claim that `COHORT_ID = 1` causes higher adverse event risk.

## Reliability Assessment

Dimension | Assessment | Rationale
--- | --- | ---
Question-data fit | Moderate to strong | The dataset supports a binary comparative-risk question, and unsupported time-to-event or incidence-rate questions were explicitly avoided.
Protocol transparency | Strong | Research question, design, methods, diagnostics, outputs, and limitations were documented before analysis execution.
Reproducibility | Strong | R scripts and markdown artifacts were created for intake, research question selection, analysis execution, interpretation, and reporting.
Data quality | Strong within the file | Required columns were present, no required fields were missing, `PERSON_ID` was unique, and binary fields contained valid values.
Design validity | Moderate | A retrospective active-comparator cohort design fits the file, but source cohort definitions, index timing, exposure history, and outcome timing are unavailable.
Confounding control | Limited to moderate | Adjustment used all available covariates, but only four measured covariates were available and LDL remained imbalanced after weighting.
Positivity and overlap | Moderate | Propensity scores overlapped without extreme 0/1 scores, but some target-cohort records had large weights.
Effect consistency | Strong | Crude, adjusted logistic, weighted risk, and subgroup summaries all showed higher adverse event risk in the target cohort.
Calibration and bias diagnostics | Weak | No negative controls, positive controls, empirical calibration, or external replication were available.
Generalizability | Weak | Source population, care setting, cohort definitions, and outcome ascertainment process are unknown.

## Key Strengths

- The work followed a documented journey from data intake to protocol, analysis, interpretation, and report.
- The analysis was performed in R with reproducible scripts.
- The selected study design matched the information available in the dataset.
- Unsupported methods, including Cox models and incidence-rate models, were explicitly ruled out.
- Data quality checks passed for required fields, identifiers, and binary variable validity.
- Results were directionally consistent across crude, adjusted, and propensity-score weighted analyses.
- Diagnostics were reported rather than hidden, including balance and weight limitations.

## Key Reliability Concerns

- The clinical meanings of `COHORT_ID` and `AE` are unknown from the file alone.
- No index dates, exposure dates, event dates, censoring dates, or person-time were available.
- The adverse event window was assumed comparable across cohorts but could not be verified.
- Only age, race, pain level, and LDL were available for confounding adjustment.
- LDL remained imbalanced after weighting, with weighted absolute standardized mean difference of 0.174.
- The maximum inverse probability weight was 25.05, and 3.58% of target-cohort records had weights greater than 10.
- No negative control outcomes, positive control outcomes, empirical calibration, chart validation, or external replication were available.
- Race was included as an available baseline covariate, but the file does not explain how race was collected, categorized, or whether it represents social, administrative, or clinical constructs.

## Evidence Readiness Rating

Evidence readiness: **hypothesis-generating / internally informative**.

This study is suitable for:

- Internal scientific review.
- Demonstrating a transparent analytic workflow.
- Prioritizing whether a more complete study is warranted.
- Informing protocol development for a larger OHDSI network-style study.
- Generating safety or quality-improvement hypotheses for follow-up.

This study is not suitable for:

- Definitive causal claims.
- Product labeling or regulatory decision-making.
- Clinical guideline recommendations.
- Public-facing claims of harm or safety.
- Comparative effectiveness or safety conclusions without further validation.

## Recommended Dissemination Language

Recommended wording:

> We conducted a transparent exploratory observational analysis of a de-identified patient-level analytic dataset. Target cohort membership was associated with higher adverse event risk after measured covariate adjustment. Because the dataset lacked source clinical definitions, timing, person-time, rich confounder measurement, and empirical calibration, these findings should be considered hypothesis-generating and should be validated in a fully specified observational study before clinical or policy use.

Avoid wording such as:

- "The target exposure caused adverse events."
- "This study proves the target cohort is unsafe."
- "These results should change clinical practice."
- "The risk estimate is generalizable to all patients."

## Recommended Next Steps Before Stronger Dissemination

1. Obtain source documentation for cohort construction, outcome definition, eligibility criteria, index date, time-at-risk, and outcome ascertainment.
2. Rebuild the study in a longitudinal data structure, preferably an OMOP Common Data Model environment if available.
3. Use a true new-user active-comparator design if exposure initiation can be defined.
4. Add richer baseline covariates, including comorbidities, prior medication use, healthcare utilization, prior adverse events, calendar time, and care setting.
5. Define event timing and censoring so hazard ratios or incidence rates can be estimated when appropriate.
6. Include negative and positive control outcomes and empirical calibration if using OHDSI population-level effect estimation methods.
7. Assess covariate balance after alternative propensity-score specifications, trimming, matching, or stratification.
8. Replicate the analysis across additional databases or data partners before external dissemination.
9. Review ethical and governance requirements before sharing any result derived from patient-level data, even when de-identified.

## Dissemination Plan

Audience | Recommended material | Message framing
--- | --- | ---
Internal analytic team | Full artifact set, code, protocol, diagnostics, report | Reproducible exploratory evidence with clear limitations
Clinical/scientific stakeholders | Final report plus reliability summary | Signal requires validation before action
Methods reviewers | Protocol, R code, diagnostics, and generated tables | Assess design fit and bias risks
External/public audience | Not recommended at this stage | Evidence is not mature enough for public claim-making
Regulatory or guideline audience | Not recommended at this stage | Missing design features and validation needed

## Final Journey Artifact Checklist

Step | Work product
--- | ---
1. Read dataset | `step1_read_dataset.R`, `step1_dataset_intake.md`
2. Identify research questions | `step2_identify_research_questions.R`, `step2_research_questions.md`
3. Determine design and methods | `step3_study_design_methods.md`
4. Write protocol and analysis specification | `step4_protocol_analysis_specification.md`
5. Implement, test, and execute analysis | `step5_execute_analysis.R`, `step5_analysis_execution_summary.md`, `results/`
6. Interpret results and diagnostics | `step6_interpret_results.R`, `step6_results_interpretation.md`
7. Write final report | `step7_write_final_report.R`, `step7_final_study_report.md`
8. Evaluate reliability and dissemination | `step8_evidence_reliability_dissemination.md`

## Step 8 Completion Check

- Evidence reliability was evaluated across design, diagnostics, confounding, reproducibility, calibration, and generalizability.
- A dissemination recommendation was written.
- Appropriate and inappropriate claims were documented.
- Recommended next steps for stronger evidence generation were documented.
- Work product created: `step8_evidence_reliability_dissemination.md`.